High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: A prospective observational study in Taiwan

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Tang, Jih Luh ^a   Kung, Hsiang Chi ^a   Lei, Weng Chi ^a   Yao, Ming ^a   Wu, Un In ^b   Hsu, Szu Chun ^b   Lin, Chien Ting ^a   Li, Chi Cheng ^a   Wu, Shang Ju ^a   Hou, Hsin An ^a   Chou, Wen Chien ^b   Huang, Shang Yi ^a   Tsay, Woei ^a   Chen, Yao Chang ^b   Chen, Yee Chun ^a,c   Chang, Shan Chwen ^a   Ko, Bor Sheng ^a   Tien, Hwei Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; COTRIMOXAZOLE; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; IDARUBICIN; NYSTATIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANDIDA TROPICALIS; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INFECTION CONTROL; INFECTION RISK; INVASIVE CANDIDIASIS; LEUKEMIA REMISSION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TAIWAN; THRUSH; TREATMENT OUTCOME; LEUKEMIA, MYELOID, ACUTE; MICROBIOLOGY; MIDDLE AGED; MYCOSES; PRE-EXPOSURE PROPHYLAXIS; REMISSION; RISK FACTOR; VERY ELDERLY;

CANDIDA TROPICALIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; PRE-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 84936804320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128410     Document Type: Article

References (33)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781-803; quiz 804-785. PMID: 9564455
2. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006; 91: 1068-1075. PMID: 16885047
3. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001; 86: 862-870. PMID: 11522544
4. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012; 97: 459-463. doi: 10.3324/haematol.2011.051995 PMID: 22058198
5. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006; 91: 986-989. PMID: 16757415
6. Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother. 2014; 58: 865-873. doi: 10.1128/AAC.01525-13 PMID: 24277033
7. Hahn-Ast C, Glasmacher A, Muckter S, Schmitz A, Kraemer A, Marklein G, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010; 65: 761-768. doi: 10.1093/jac/dkp507 PMID: 20106864
8. Hammond SP, Marty FM, Bryar JM, DeAngelo DJ, Baden LR. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol. 2010; 85: 695-699. doi: 10.1002/ajh.21776 PMID: 20652970
9. Kurosawa M, Yonezumi M, Hashino S, Tanaka J, Nishio M, Kaneda M, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012; 96: 748-757. doi: 10.1007/s12185-012-1210-y PMID: 23111539
10. Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol. 2008; 81: 354-363. doi: 10.1111/j.1600-0609.2008.01122.x PMID: 18637030
11. Neofytos D, Lu K, Hatfield-Seung A, Blackford A, Marr KA, Treadway S, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013; 75: 144-149. doi: 10.1016/j.diagmicrobio.2012.10.001 PMID: 23142166
12. Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015; 100: 284-292. doi: 10.3324/haematol.2014.113399 PMID: 25638805
13. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000; 110: 273-284. PMID: 10971382
14. Chen YC, Sheng WH, Wang JT, Chang SC, Lin HC, Tien KL, et al. Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections. PLoS One. 2011; 6: e27163. doi: 10.1371/journal.pone.0027163 PMID: 22110610
15. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474. doi: 10.1182/blood-2009-07-235358 PMID: 19880497
16. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46: 1813-1821. doi: 10.1086/588660 PMID: 18462102
17. Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica. 2012; 97: 325-327. doi: 10.3324/haematol.2012.061952 PMID: 22383742
18. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 7-14. PMID: 11731939
19. Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, Palma LC, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013; 19: 745-751. doi: 10.1111/1469-0691.12002 PMID: 23009319
20. Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis. 2000; 13: 615-620. PMID: 11964830
21. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010; 50: 405-415. doi: 10.1086/649879 PMID: 20047485
22. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001; 33: 1692-1696. PMID: 11641825
23. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009; 115: 4745-4752. doi: 10.1002/cncr.24507 PMID: 19634156
24. Ruan SY, Hsueh PR. Invasive candidiasis: an overview from Taiwan. J Formos Med Assoc. 2009; 108: 443-451. doi: 10.1016/S0929-6646(09)60091-7 PMID: 19515624
25. Yang YL, Cheng MF, Wang CW, Wang AH, Cheng WT, Lo HJ, et al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med Mycol. 2010; 48: 328-334. doi: 10.3109/13693780903154070 PMID: 20141372
26. Chi HW, Yang YS, Shang ST, Chen KH, Yeh KM, Chang FY, et al. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect. 2011; 44: 369-375. doi: 10.1016/j.jmii.2010.08.010 PMID: 21524971
27. Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W, et al. Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol. 2003; 82: 93-97. PMID: 12601487
28. Girmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leuk Res. 2014; 38: 469-474. doi: 10.1016/j.leukres.2014.01.007 PMID: 24534569
29. Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012; 31: 991-997. doi: 10.1007/s10096-011-1397-5 PMID: 21909650
30. Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica. 2011; 96: 337-341. doi: 10.3324/haematol.2010.030825 PMID: 21071502
31. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002; 94: 3230-3246. PMID: 12115356
32. Cornely OA, Bohme A, Buchheidt D, Glasmacher A, Kahl C, Karthaus M, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82 Suppl 2: S186-200. PMID: 13680164
33. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-359. PMID: 17251531